Forest's Saunders ropes 2nd major sale, boosts personal brand in Actavis deal
This article was originally published in Scrip
Forest Laboratories president and CEO Brent Saunders has positioned himself as a most-wanted man in the biopharma industry with his second multibillion-dollar sale of a specialty pharmaceutical company in less than a year.
You may also be interested in...
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.